Evidence map›Paper›PMID 38319108›Full record

Trial reportMicrobiology spectrum2024

Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster.

Jingmin Zhao, Han Zhang, Lina Jiang, Fang Cheng, Wei Li, Zihao Wang, Hongyang Liu, Shaohua Li, Yiyun Jiang, Meiling Li and 8 more

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Jingmin Zhao *Department of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.ORCID 0000-0003-4345-2149
Han Zhang *CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
Lina Jiang *Department of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Fang Cheng *CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
Wei Li *Department of Infectious Diseases, First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Zihao WangCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
Hongyang LiuDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Shaohua LiDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Yiyun JiangDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Meiling LiDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Yan LiDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Shuhong LiuDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Min FangCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.ORCID 0000-0002-5278-1430
Xuyu ZhouCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
Xin YeCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
Shousong ZhaoDepartment of Infectious Diseases, First Affiliated Hospital of Bengbu Medical College, Bengbu, China.ORCID 0000-0002-8076-518X
Yuxuan ZhengHuman Phenome Institute, Fudan University, Shanghai, China.ORCID 0000-0002-7407-5684
Songdong MengCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.ORCID 0000-0001-5670-1533
Chinese PLA General Hospital · CNChinese Academy of Sciences · CNFirst Affiliated Hospital of Bengbu Medical College · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is urgently needed to evaluate the necessity and benefits of booster vaccination against the coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2) Omicron to facilitate clinical decision-making for 2019 coronavirus disease (COVID-19) convalescents. We conducted a multicenter, prospective clinical trial (registration number: ChiCTR2100045810) in the first patients with COVID-19 from 28 January 2020 to 20 February 2020 to assess the long-term durability of neutralizing antibodies against live Omicron BA.5 and further assess the efficiency and safety of CoronaVac in the convalescent group. A total of 96 COVID-19 convalescents were enrolled in this study. Neutralizing antibody titers in convalescents were significantly reduced in 9-10 months. A dose-refreshing vaccination in 28 convalescents with an antibody titer below 96 significantly induced neutralizing antibodies against live Omicron by 4.84-fold. Meanwhile, the abundance of naive T cells increased dramatically, and T

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralAntiviral AgentsApoptosisHumansProspective StudiesSARS-CoV-2T-LymphocytesVaccinationVaccines, InactivatedAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsVaccines, Inactivatedcell deathconvalescentsOmicronSARS-CoV-2T cellsvaccine

Identifiers

PMID38319108
PMCPMC10913726
OpenAlexW4391577103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.